Lots of FDA Guidance, But Few Drug Manufacturing “Remote Interactive Evaluations” (We Would Call Them “Virtual Inspections”) By Douglas B. Farquhar & Richard A. Lewis, Senior Regulatory Device & Biologics Expert —

https://www.thefdalawblog.com/2023/11/lots-of-fda-guidance-but-few-drug-manufacturing-remote-interactive-evaluations-we-would-call-them-virtual-inspections/?utm_source=rss&utm_medium=rss&utm_campaign=lots-of-fda-guidance-but-few-drug-manufacturing-remote-interactive-evaluations-we-would-call-them-virtual-inspections